Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY.
加利福尼亚州弗里蒙特，2024年11月20日（环球新闻社）- 麦克生物科技公司（纳斯达克股票代码：CTKB），一家领先的细胞分析解决方案公司，今天宣布公司将参加即将举行的第36届派杰投资健康医疗大会，地点为纽约，纽约。
Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
麦克管理团队定于2024年12月3日星期二下午4:30（东部时间1:30（太平洋时间）参加炉边聊天。有兴趣的各方可以在公司网站的“投资者”栏目上查看演示的现场直播和存档网络广播，网址为：investors.cytekbio.com。
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .
纳斯达克:CTKB是引领细胞分析解决方案的公司，通过提供高分辨率、高内容和高灵敏度的细胞分析工具，推动下一代细胞分析工具。利用其拥有专利的全光谱分析（FSP）技术，Cytek的新颖方法利用荧光信号全谱中的信息力量，实现更高水平的多重化，具有精准性和灵敏度。Cytek的FSP平台包括其核心仪器Cytek Aurora和Northern Lights系统；其分选机Cytek Aurora CS；Cytek Orion试剂混合系统；增强小颗粒（ESP）检测技术；Amnis和Guava品牌下的流式细胞仪和成像产品；以及试剂、软件和服务，为客户提供全面和集成的解决方案套件。Cytek总部位于加利福尼亚州弗里蒙特，分布全球各地的办公室和分销渠道。有关公司及其产品的更多信息，请访问。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的产品仅供研究使用，不用于诊断程序（除了中国和欧盟的Cytek Northern Lights-CLC系统和某些试剂可用于临床使用）
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、Full Spectrum Profiling、FSP、Cytek Aurora、Northern Lights、Cytek Orion、Enhanced Small Particle、ESP、Amnis和Guava是Cytek Biosciences, Inc.的商标。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向证券交易委员会（SEC）提交文件、新闻稿、公开电话会议和网络直播外，Cytek还将其网站（）、LinkedIn页面和X（前称Twitter）账户用作分发有关公司、产品、拟定的财务和其他公告、参加即将举行的投资者和行业会议以及其他事项的信息渠道。这些信息可能被视为重要信息，Cytek可能使用这些渠道以遵守根据FD法规的披露义务。因此，投资者应该监控Cytek的网站、LinkedIn页面和X账户，以及关注其证券交易委员会提交的文件、新闻发布、公开电话会议和网络直播。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒体联系：
Stephanie Olsen
Lages＆Associates
（949）453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投资者联系人：
Paul Goodson
投资者关系主管
Cytek Biosciences
pgoodson@cytekbio.com
